SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema, Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results
Olema Oncology Announces Publication of Data Highlighting Palazestrant™s Ability
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema, Olema Oncology, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal...
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema, Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...